Peachfaced Lovebird Genetics Calculator Version 1.5 - Program by Doug Bedwell Welcome to the Peachfaced Lovebird Genetics Calculator. This program is written in the Java (tm) programming language. Most web browsers now support JAVA code, but If all you see below this text is an empty space, then you are not using a Java compatible web browser. Sorry. This program allows you to quickly calculate the possible color combinations that can result from a pairing of any two peachfaced lovebirds. I have tried to include the most commonly available peachfaced mutations, though some have been omitted. All known mutations will be included in a later version of the program. Several caveats about this program: 1. You will need to know enough about your parent birds to tell the program what mutations they carry. 2. The program only uses the accepted names for color mutations, and does not insert special names for combinations. For example, a "Creamino" will be shown as a "Dutch Blue Lutino", and a "Slate" will be shown as a "Dark Dutch Blue." Future improvements may include: Percentage possibilities of each color combination occurring. Ability to print out results. Additional mutations (American Yellow, etc.) Seperate listings of visual … Continue reading →

MEDIA RELEASE For Immediate Release 9 July 2014 Liberty Genetics bull teams make major genetic gains over past decade Herd improvement company, Liberty Genetics, today released ten years of breeding worth (BW) statistics on its Jersey, Friesian and Crossbred bull teams. The numbers show that the BW values of its bull teams are ranking well against the other top sire teams in the country. Dr Dave Hayman, Liberty Genetics Manager of Genetic Development, said, On average, across our three sire teams theres only around five BW difference between our sire team and other top performing teams. This includes NZ Animal Evaluations adjustments for young bulls. Dr Hayman has overseen the companys breeding programme since 2006. He said the most impressive statistics are for Liberty Genetics Jersey bull team, which show an average annual BW gain of $15 year-on-year over the past decade; a gain of 146 BW in ten years. Our team is right up with the top Jersey teams in New Zealand with the average BW for our 2014 Jersey bull team sitting at $243. BW is the basis on which New Zealand ranks dairy bulls and cows based on their expected ability to produce profitable and efficient replacements. … Continue reading →

The University of Tennessee Health Science Center is amplifying its research, teaching and medical care involving genetics with the creation of a genetics department, officials announced. Robert W. Williams, an experimental neurogeneticist on the universitys faculty for 25 years, is the founding chairman of the new Department of Genetics, Genomics and Informatics. Williams is the UT-ORNL Governors Chair in Computational Genomics, a program funded by the state and the Oak Ridge National Laboratory. Forming this department significantly improves our research prospects in the next wave of human genetics, while building on strengths in experimental, molecular and quantitative genetics, Williams said. The new department is starting with a core faculty of five. Others will be added from UTHSC and elsewhere, including St. Jude Childrens Research Hospital and the University of Memphis. The department will function as a cross-disciplinary, interdepartmental and intercollegiate unit, and serve as a catalyst for research and teaching, said Dr. David Stern, executive dean of the universitys College of Medicine. Originally posted here: New department at UT in Memphis focuses on genetics … Continue reading →

LONDON und LAUSANNE, Schweiz, July 8, 2014 /PRNewswire/ -- Investition soll Nutzung klinischer Analysen fr genetisch bedingte Krankheiten in Europa beschleunigen Sophia Genetics, das fhrende europische Unternehmen im Bereich datengesttzter Medizin, hat in einer Serie-B-Finanzierungsrunde 13,75 Millionen US-Dollar an Mitteln beschafft, angefhrt durch Invoke Capital von Mike Lynch, Swisscom und Endeavour Vision. Sophia Genetics ist ein Pionier in der datengesttzten Medizin, einem bergreifenden Gebiet, das umfangreiche Kompetenz mit Next Generation Sequencing (NGS) erfordert, kombiniert mit uerst genauen und skalierbaren voraussagenden Algorithmen zur Diagnose genetisch bedingter Erkrankungen. Mit dieser Investition verschafft sich Sophia Zugang zu Genalys, einem Unternehmen aus dem Portfeuille von Invoke, dessen in Cambridge angesiedelte Mathematiker Big-Data-Verfahren auf Genomdaten anwenden. Die Kombination bedeutet, dass Kliniker und Krankenhuser in ganz Europa Zugriff auf einen uerst genauen klinischen Analysedienst zur frhzeitigen Diagnose und optimierten Behandlung von Krebs und genetisch bedingten Erkrankungen erhalten. Patienten knnen ihre DNA und ihre Krebstumor-DNA schneller und gnstiger denn je sequenzieren lassen, was bedeutet, dass sich die Krankheit einer einzelnen Person wesentlich besser nachvollziehen lsst als noch vor einigen Jahren. Dr. Mike Lynch sagte: "Die Herausforderung liegt jetzt in der Analyse, der Interpretation und dem Schutz der riesigen Mengen von Sequenzdaten, die durch diese neue Technologie generiert … Continue reading →

LONDRES et LAUSANNE, Suisse, July 8, 2014 /PRNewswire/ -- L'investissement a pour but d'acclrer l'adoption europenne des analyses cliniques des pathologies gntiques Sophia Genetics, leader europen dans le domaine de la mdecine base sur les donnes, a obtenu 13,75millions$ au cours d'un tour de financement de srie B organis par Invoke Capital - une socit fonde par le Dr Mike Lynch - Swisscom et Endeavour Vision. Sophia Genetics est un pionnier en matire de mdecine base sur les donnes, un domaine de convergence ncessitant une expertise approfondie en matire de squenage de prochaine gnration (NGS) associe des algorithmes trs prcis, extensibles et prdictifs pour le diagnostic des pathologies gntiques. Grce cet investissement, Sophia peut accder Genalys, une socit appartenant Invoke dont les mathmaticiens bass Cambridge traitent les informations gnomiques avec des mthodes big data. Cette combinaison signifie que les cliniciens et les hpitaux dans l'ensemble de l'Europe peuvent obtenir des analyses cliniques trs prcises pour le diagnostic prcoce et le traitement optimis du cancer et des pathologies gntiques. L'ADN des patients et celui de leurs tumeurs cancreuses peuvent tre squencs avec une rapidit et selon des cots ingals, ce qui signifie que la pathologie d'une personne peut tre comprise de … Continue reading →